logo-loader
viewBioPharmX

BioPharmX shares pop after regaining compliance with NYSE American's listing standards

The pharma group specializing in dermatological products also narrowed its net loss in the fiscal first quarter

Pills
BioPharmX shares are trading higher in the pre-market session

Shares of BioPharmX (NYSE American: BPMX), a Silicon Valley-based pharmaceutical group specializing in dermatological products, picked up steam in pre-market trade after reporting a narrowing of its net loss in its fiscal first-quarter.

Investors also seemed enthused by BioPharmX’s report that it regained compliance with NYSE American’s continued listing standards as of June 1.

In pre-market trade, BioPharmX’s shares climbed 5.6% to US$0.26.

For the three months until April’s close, BioPharmX recorded a net loss of US$0.02 per share or US$4.4mln, which was a better show than analysts’ expected forecast of a loss of US$0.03 per share.

In the year-ago first fiscal quarter, BioPharmX lost US$0.08 per share or US$5.4mln.

The company’s cash and cash equivalents came to US$10.9mln at the close of April.

BioPharmX’s two lead drug treatments are BPX-01, which treats acne, and BPX-04, which fights rosacea. The acne drug has completed Phase 2b studies and is preparing for Phase 3 trials while the rosacea treatment is still preparing for Phase 2 trials.

Quick facts: BioPharmX

Price: 0.4298 USD

NYSEMKT:BPMX
Market: NYSEMKT
Market Cap: $7.86 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: RPM Automotive announces key appointments and growth...

RPM Automotive Group Ltd (ASX:RPM) managing director Clive Finkelstein and newly appointed non-executive director Alex Goodman update Proactive on a number of key appointments to the board since the company listed on the ASX late year. The MD spoke about the key successes and challenges...

10 hours, 7 minutes ago

2 min read